Pharmaceutical company Lupin unveils plans to showcase Phase 1 data on LNP7457, a PRMT5 inhibitor, during the American Society of Clinical Oncology's Annual Meeting in 2025.
India-based pharmaceutical company, Lupin Limited, presented Phase 1a clinical trial data for their PRMT5 inhibitor, LNP7457, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. The presentation, titled 'A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors,' was featured in the Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology session.
The trial aimed to evaluate the safety and efficacy of LNP7457 in patients with advanced or metastatic solid tumors. While the publicly available information from the announcements around the event primarily confirms the presentation of these trial data, specific details on the efficacy and safety outcomes of LNP7457 have not been disclosed in the sources accessible from these search results.
Lupin's workforce consists of over 23,000 professionals, and their products are distributed in over 100 markets worldwide. The company is committed to improving patient health outcomes through its subsidiaries - Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Lupin's current data indicates that LNP7457 is unique within its field and appears to be safe and well-tolerated as a SAM-competitive PRMT5 inhibitor. The abstract number for the presentation is 3107 and can be accessed at
Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India. The company is not specifically mentioned as a global pharma major in this paragraph, but it enjoys a strong position in India and the U.S. across multiple therapy areas. To learn more about Lupin, visit www.lupin.com or follow them on LinkedIn (
References: [1] Lupin Limited. (2025, May 30). Lupin presents data from a Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025. Retrieved from
[2] American Society of Clinical Oncology. (2025). ASCO 2025 Annual Meeting. Retrieved from
- The news about Lupin Limited's presentation at the ASCO annual meeting in Chicago, Illinois, highlighted the Phase 1a clinical trial data for their PRMT5 inhibitor, LNP7457, which is a potential treatment for medical-conditions like cancer.
- Aside from confirming the presentation of LNP7457's trial data, no specific details about the efficacy and safety outcomes have been disclosed yet, such as its impact on health-and-wellness or other scientific aspects.
- With over 23,000 professionals, Lupin Limited is a global pharmaceutical company dedicated to research and development across various therapy areas, including diagnostic solutions (Lupin Diagnostics), digital health services (Lupin Digital Health), and manufacturing solutions (Lupin Manufacturing Solutions), all aimed at improving patient health outcomes.
